Document is current
Any future updates will be listed below
-
Authors
Tian, Zeru
Wang, Xu https://orcid.org/0000-0002-8925-5645
Chatterjee, Sumanta
Miller, William https://orcid.org/0000-0002-6096-0711
Guerrero, Erick
Sung, Yun-Chieh
Benitez, Alexis Pacheco
Dilliard, Sean
Bian, Xiaoyan
Vaidya, Amogh https://orcid.org/0000-0003-0712-659X
Lian, Xizhen
Moore, Stephen
Sun, Yehui https://orcid.org/0000-0003-0215-6095
Kim, Minjeong
Xiao, Yufen https://orcid.org/0000-0002-5604-7479
Wu, Shiying https://orcid.org/0000-0002-6902-9544
Evers, Bret M. https://orcid.org/0000-0001-5686-0315
Lee, Jeon
Farbiak, Lukas https://orcid.org/0000-0003-4107-1676
Siegwart, Daniel J. https://orcid.org/0000-0003-3823-1931
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (5R01EB025192-06)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA269787-01)
Welch Foundation (I-2123-20220031)
- License Information
-
More Information
Article History
Received: 29 July 2024
Accepted: 15 December 2025
First Online: 17 March 2026
Competing interests
: A provisional patent application covering compounds and compositions for targeting lung has been filed by UTSW naming D.J.S, Z.T. and X.W. as inventors. D.J.S. discloses financial interests in ReCode Therapeutics, Signify Bio, Jumble Therapeutics and Tome Biosciences. D.J.S. is a member of the scientific advisory board of ReCode Therapeutics, which has licensed intellectual property from UTSW. The remaining authors declare no competing interests.
